India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

AbbVie licensed IGI's trispecific myeloma drug ISB 2001 in a deal worth up to $1.925 billion following strong early-phase ...

A high-stakes bet on a biotech underdog could reshape the global cancer treatment landscape--and boost Glenmark's profile ...

The deal hands AbbVie a drug that’s shown early promise in multiple myeloma and may be useful treating other cancers and ...

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement (updated August 13, 2024) ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

The deal also entails $1.23 billion in milestone payments. While Glenmark unit IGI will retain rights for India and emerging ...

We came across a bullish thesis on AbbVie Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ ...

Glenmark's Ichnos Glenmark inks licensing deal with AbbVie for ISB 2001, a cancer and autoimmune disease drug. AbbVie gets ...

AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

Under the agreement, AbbVie will get exclusive rights to develop, manufacture and commercialize ISB 2001 in North America, ...